Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by D. Meskine.
Journal of Endocrinology and Diabetes Mellitus | 2013
Farida Chentli; Said Azzoug; D. Meskine; Fetta-Amel Yaker; Fadila Chabour; Hayet Boudina
Cushing syndrome (CS) is scarcely observed in males. Because of this rarity, the real prevalence of gonadal dysfunction in men with hypercortisolism is unknown. Our aim was to analyze gonadal abnormalities in 37 males with CS (median age=28.9±11years) comparatively to age matched healthy men (n=10). For the homogeneity of the study men over 50, children, patients taking medications and those with pituitary deficits were systematically excluded. For the remaining group, we took into account medical history, clinical examination, and hormonal assessment, by radio immunoassay, for testosterone (T), prolactin (PRL), follicle stimulating hormone (FSH), and luteinizing stimulating hormone (LH). Results: 21% consulted for impotency and/or gynecomastia. When questioned, 65.7% complained about decreased libido and erectile dysfunction. Except for 3, body hair growth and repartition, and testicular volume were normal. Gynecomastia was observed in 18.9%.Testosterone was equal to 2.79±1.62ng/ml vs 6.69±3.87ng/ml (p<0.0005). Low testosterone (<3ng/ml) was observed in 67.5%. PRL =9.8 ± 4.2ng/ml vs 4.9 ± 2.6ng/ml (p<0.01). FSH = 3.87 ± 1.9mu/ml vs 3.75 ± 2.25mU/ml (p<0.30). LH = 2.7 ± 2.2mU/ml vs 3.66 ± 0.86 (p<0.30). We have not found any correlation between cortisol and T, PRL or LH, but there was a positive and significant one with FSH (r=0.57, p<0.005). Conclusion: CS causes a franc hypogonadism in 65%. According to FSH and LH results glucocorticoids excess acts probably at hypothalamic pituitary level, but an increase in testosterone degradation and/or inhibition of testis receptors cannot be ruled out. So men with hypogonadism and/or gynecomastia should be systematically checked for CS.
Hormone Research in Paediatrics | 2012
Farida Chentli; Said Azzoug; Mohammed El Amine Amani; A.E.M. Haddam; Dalal Chaouki; D. Meskine; Mohamed Lamine Chaouki
Background/Aims: True gigantism is an exceptional and fascinating pediatric disease. Our aim in this study was to describe the different etiologies of a large group of children with gigantism and the natural history of their growth. Methods: In this multicenter study, we considered as giant children, adolescents and adults whose heights were ≥3 SD compared to their target stature or to our population average lengths. Isolated hypogonadism and Klinefelter syndrome were excluded from this series. All underwent clinical exam, and hormonal and neurological investigations. Results: From 1980 to 2010, we observed 30 giants: 26 males (86.6%) and 4 females (mean age 19.8 ± 11 years). Among the 13 patients (40.3%) who consulted before the age of 16 years, 9 had acromegaly and 6 had mental retardation and body malformations. Based on growth hormone (GH) secretion evaluation, 2 groups were observed: pituitary gigantism (n = 16): GH = 150 ± 252 ng/ml (n ≤ 5), and other causes with normal GH (0.7 ± 0.6 ng/ml): 6 Sotos syndrome and 8 idiopathic cases. Only the first group had neurological, ophthalmological, metabolic and cardiovascular complications and received treatment. The result was not optimal as GH normalization was not observed. Reduction of tumor size and decreased GH plasma values were not observed. Conclusion: Gigantism predominates in males. The main cause is GH excess. The diagnosis was very late except for cerebral gigantism. Complications were observed in pituitary gigantism only.
Journal of Endocrinology and Diabetes Mellitus | 2016
Nora Soumeya Fedala; Leyla Ahmed Ali; Farida Chentli; D. Meskine; A.E.M. Haddam
Polycystic ovarian disease (PCOS) is the most common endocrine disorder among women in genital activity (prevalence: 5 and 10%). It is a frequent cause of hirsutism and infertility in women and affects 3-10% of women overall population. Whatever the age of onset, PCOS predisposes to metabolic and early cardiovascular complications. The PCOS is frequently associated with obesity, insulin resistance and hyperinsulinemia. There is a greater risk of glucose intolerance, diabetes mellitus (10%) and hyperlipidemia (more than half of women). The aim of our study was to report the frequency of metabolic syndrome (MS) in PCOS and specify its clinical and biological characteristics. This is a prospective, descriptive study which concerned 66 primary PCOS patients. The frequency of metabolic syndrome was 48.5%. The average age was 33.9 ± 9.22 years (16 – 45) Just under half of the patients (42.4%) were obese at diagnosis. The mean BMI was 32.4 kg / m2 ± 0.3. A slightly more than 2/3 of PCOS patients (72.6%) have a and roidobesity. The average waist circumference PCOS patients was 87.5 ± 0.1 cm. Nearly a third of patients have abnormal glucose tolerance. They have an average triglycerides, mean arterial pressure, mean blood glucose, insulin and an average index HOMA significantly higher (p: 10- 3). Their HDL level is significantly reduced (p <10-3). A little over a quarter of PCOS patients with metabolic syndrome: 37.5%) have all of the risk factors for MS at diagnosis.
17th European Congress of Endocrinology | 2015
A.E.M. Haddam; Nora Soumeya Fedala; Leyla Ahmed Ali; D. Meskine; Farida Chentli
20 children (chronological age at diagnosis: 8 ± 1.8 years) at the end of treatment (11 ± 0.1 years) and the final size (15.9 ± 2.5 years) were treated for a central precocious puberty. the selection criteria for this study were treatment of central precocious puberty by Decapeptyl® during two years or more. We assessed pubertal status, size , bone maturation at the beginning and the final size after stop taking treatment and its side effects
Indian Journal of Endocrinology and Metabolism | 2014
Farida Chentli; Said Azzoug; D. Meskine; Aldjia El Gradechi
Background: Nowadays diabetes mellitus (DM) is one of the greatest global challenges. Its expansion varies from an area to another according to genetic, traditions, socio-economic conditions, and stress. In Algeria, as in other emerging countries undergoing an epidemiological transition, noncommunicable diseases are sharply increasing. After high blood pressure, DM is now the second metabolic disease. But are women more concerned by DM since obesity frequency is higher in females? Can we assert that there is a sort of sex discrimination for DM complications? Materials and Methods: To answer these questions we took into account published documents carried in Algerian population. But, as those were very scarce, we also considered newspapers articles, some documents published by health minister department, posters and oral communications of the Algerian Society of Endocrinology and Diabetology, and our clinical experience. We also have done a small survey to get our patients’ opinions. Results and Conclusion: At the first sight, it seems gender discrimination between men and women cannot exist since most epidemiological studies showed that both sexes are broadly and equally affected by DM, except for old aged females who are the most affected. When we reconsidered the problem, and when we compared past results to those obtained after the terrorism period, many studies showed a sort of gender difference. Apart from gestational DM, which is increasing sharply, some complications and death related to DM are prevailing in women. Coronary diseases and cerebral vascular accidents are more frequent in women too, especially the young ones and those suffering from DM. These complications are probably due to the recent and rapid modification in womens lifestyle with a strong reduction in physical activity, eating disorders, hormonal contraception, and high sensitivity to perceived stress secondary to the near past stressing life and/or to numerous responsibilities taken by women in the modern society.
Annales D Endocrinologie | 2013
Nora Soumeya Fedala; A.E.M. Haddam; H. Boulaam; D. Meskine; Farida Chentli
P1-084 Manifestations endocrines du syndrome de Woodhouse-Sakati, revue exhaustive de la littérature M. Agopiantz a,∗, A. Sorlin b, P. Corbonnois c, C. Bonnet b, M. Klein a, P. Jonveaux b, T. Cuny a, G. Weryha a a Service d’endocrinologie et de gynécologie médicale, CHU de Nancy, Nancy, France b Laboratoire de génétique, CHU de Nancy, Nancy, France c Service de diabétologie, CHU de Nancy, Nancy, France ∗Auteur correspondant.
Annales D Endocrinologie | 2013
A.E.M. Haddam; Nora Soumeya Fedala; D. Meskine; Farida Chentli
L’hyperaldostéronisme primaire (HAP) est une cause rare mais curable d’HTA. Son diagnostic doit être précoce afin de réduire la morbidité liée a cette affection. Objectif.– Rapporter la fréquence de l’hyperaldostéronisme primaire dans les incidentalomes surrénaliens et ses caractéristiques phénotypiques. Population et méthodologie.– Cent quatre-vingt patients porteurs d’incidentalomes surrénaliens ont été explorés sur le plan clinique hormonal et radiologique afin de rechercher une hypersécrétion corticoou médullosurrénalien. Résultats.– Vingt cas (11,1 %) d’hyperaldostéronisme primaire ont été recensés. Quinze avaient un adénome de Conn et 5 une hyperplasie primitive. Le sex-ratio était de 1, l’âge moyen au diagnostic était de 52 ans (20–59). Tous avaient une HTA sévère connue depuis 10,6 ans en moyenne (3–23), compliquée dans 2/3 des cas et non explorée. Une hypokaliémie symptomatique était observée dans 57 % des cas. La taille moyenne de l’adénome surrénalien était de 21,45 × 16 mm avec une prédominance du côté droit (4/7). Le traitement chirurgical de l’adénome et ont permis de normaliser la TA dans 40 % des cas et la kaliémie dans tous les cas. Le traitement par spironolactone a permis de stabiliser le tableau clinique et biologique dans les cas d’hyperplasie. Discussion et conclusion.– L’HAP est la cause d’HTA endocrinienne la plus fréquente. Son diagnostic doit être évoqué systématiquement si la TA est sévère ou qu’il s’y associe une masse surrénalienne. L’hypokaliémie n’est pas constante. Les objectifs du traitement des HAP sont la normokaliémie et la normotension. La recherche d’un adénome permet de trancher entre la chirurgie ou le traitement médical.
Annales D Endocrinologie | 2013
N. Fafa; S. Fedala; L. Kedad; A.E.M. Haddam; D. Meskine
Introduction.– Les vipomes sont des tumeurs neuroendocrines très rares, siégeant dans plus de 90 % des cas au niveau du pancréas, ils peuvent s’inscrire dans le cadre d’un néoplasie endocrinienne type 1 dans 5 à 15 % des cas. Observation.– Patiente de 49 ans, hospitalisée pour diarrhée cholériforme et troubles hydro-électrolytiques majeurs. Le diagnostic du vipome est évoqué devant une diarrhée majeure et une hypokaliémie sévère. Le dosage du VIP sanguin est revenu > 200 pg/mL (VN < 60 pg/mL). la recherche d’une NEM1 est revenu négative, ainsi que les dosages de sérotonine, 5 HIAA urinaires, ACE, Ca19-9, FP et NSE. L’écho-endoscopie a montré la présence d’une formation tumorale pancréatique de 2 cm. La tomodensitométrie et l’IRM retrouvent une lésion suspecte du foie de 5 cm dont la biopsie a révélé un aspect de tumeur neuroendocrine exprimant la chromogranine et la synaptophysine. La scintigraphie aux récepteurs de la somatostatine a objectivé deux fixations pancréatique et hépatique. Après réhydratation hydro-électrolytique et sandostatine suivies d’une efficacité spectaculaire. La patiente est opérée, L’étude anatomopathologique conclu à une localisation pancréatique d’un carcinome bien différencié, immunoréactif au VIP, chormogranine et synaptophysine. Trois ans après, pas de récidive. Conclusion.– Malgré une malignité rapportée dans 50 à 60 % des cas s’accompagnant de métastases ganglionnaires et/ou hépatiques au moment du diagnostic, le vipome reste accessible à la chirurgie qui elle seule permet la guérison si l’exérèse complète de la tumeur et des métastases est réalisée.
Annales D Endocrinologie | 2012
A.E.M. Haddam; S. Ouahid; N. Fafa; L. Kedad; D. Meskine
Introduction.– Les macroadénomes hypophysaires peuvent (de part leur taille et leur siège) entraîner des troubles hypothalamiques en dehors de toute intervention chirurgicale. Peu d’études se sont intéressées à ces anomalies. Méthodologie.– Le rythme biologique a été évalué par un questionnaire chez 6 patients (3 H, 3 F) hospitalisés pour macroadénome hypophysaire. Résultats.– Cinq adénomes à PRL et 1 silencieux ont été explorés. L’âge variait entre 26 et 42 ans. Tous les hommes avaient un processus géant ≥ 4 cm. La taille tumorale était comprise entre 20 et 35 mm chez les femmes. L’expansion tumorale était à prédominance suprasellaire. L’état de vigilance était conservé chez tous les patients. Quatre des six patients avaient des troubles du sommeil et de l’appétit. La durée moyenne du sommeil variait entre 4 et 9 heures avec une perturbation particulièrement nette chez trois patients. Discussion-Conclusion.– Ces dysfonctionnements peuvent être expliqués du moins en partie par la compression tumorale hypothalamique des noyaux supraoptiques. La répercussion de l’adénome sur le rythme biologique implique un dysfonctionnement de la voie rétinohypothalamique ce qui provoque des perturbations du cycle nycthéméral dans la plupart des cas marqués par des insomnies et par une anorexie.
Revue Francophone Des Laboratoires | 2009
A.E.M. Haddam; Dalila Foudil; Nora Soumeya Fedala; Lyes Yargui; Fawzi Bakiri; D. Meskine
Resume L’insuffisance antehypophysaire traitee de facon conventionnelle expose a des complications metaboliques et cardiovasculaires augmentant la morbi-mortalite de facon significative. 46 patientes avec syndrome de Sheehan ont ete comparees a 51 sujets temoins. Les patientes ont une obesite androide avec un tour de taille significativement superieur a celui des temoins malgre un indice de masse corporelle (IMC) comparable. Par ailleurs les patientes ont une moyenne des triglycerides significativement plus elevee que les temoins, une moyenne d’HDL-c significativement plus basse et un rapport d’atherogenicite cholesterol total/HDL-c significativement plus eleve chez les patientes.